The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. Until today this year the stock’s price performance recorded an increase of 33.39%. However, over the last six months, the performance has been weaker by 28.19%. The price of HALO decreased -11.76% over the last 30 days. And in the last five days, it has fallen by -5.70%.
The stock market performance of Halozyme Therapeutics Inc. has been very steady. Over the last year, the company’s stock hit its highest at $65.53 on 08/29/24, while the lowest price during the same time frame was $32.83, recorded on 10/25/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of HALO Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Halozyme Therapeutics Inc.’s current trading price is -24.77% away from its 52-week high, while its distance from the 52-week low is 50.17%. The stock’s price range for this period has been between $32.83 and $65.53. The Healthcare sector company’s shares saw a trading volume of about 1.04 million for the day, which was lower than the average daily volume of 1.33 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Halozyme Therapeutics Inc. (HALO) has experienced a quarterly decline of -12.32% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 6.25B and boasts a workforce of 373 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 55.42, with a change in price of +4.25. Similarly, Halozyme Therapeutics Inc. recorded 1,379,591 in trading volume during the last 100 days, posting a change of +9.43%.
HALO’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for HALO stands at 5.19. Similarly, the long-term debt-to-equity ratio is also 5.19.
HALO Stock Stochastic Average
As of today, the raw stochastic average of Halozyme Therapeutics Inc. over the last 50 days is at 1.10%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 1.40%. Further, the company’s Stochastic %K and %D values for the last 20 days were 8.79% and 13.95%, respectively.
